SGMT trades 103.0% below Wall Street's consensus target of $20.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SGMT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Sagimet Biosciences Inc. (SGMT) has a Wall Street consensus price target of $20.00, based on estimates from 9 covering analysts. With the stock currently trading at $9.85, this represents a potential upside of +103.0%. The company has a market capitalization of $321M.
Analyst price targets range from a low of $7.00 to a high of $29.00, representing a 110% spread in expectations. The median target of $22.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SGMT trades at a trailing P/E of -11.1x. Analysts expect EPS to grow -27.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MDGLMadrigal Pharmaceuticals, Inc. | $9.2B | $399.63 | $684.80 | +71.4% | Buy | — | 25 |
 AKBAAkebia Therapeutics, Inc. | $108M | $0.40 | $1.00 | +149.2% | Buy | — | 12 |
 HALOHalozyme Therapeutics, Inc. | $12.3B | $103.63 | $110.00 | +6.1% | Buy | 12.0x | 27 |
 ACADACADIA Pharmaceuticals Inc. | $3.6B | $21.23 | $30.05 | +41.5% | Buy | 34.1x | 37 |
 HIMSHims & Hers Health, Inc. | $5.8B | $26.00 | $32.17 | +23.7% | Hold | — | 20 |
 ALDXAldeyra The | $38M | $0.63 | $9.67 | +1426.0% | Buy | — | 19 |
 CRLCharles River Laboratories International, Inc. | $16.3B | $337.52 | $308.36 | -8.6% | Buy | 29.7x | 37 |
 IQVIQVIA Holdings Inc. | $44.7B | $271.83 | $289.91 | +6.7% | Buy | 21.0x | 45 |
 MEDPMedpace Holdings, Inc. | $18.2B | $653.11 | $646.90 | -1.0% | Hold | 35.8x | 19 |
 ICLRICON Public Limited Company | $15.7B | $204.74 | $217.69 | +6.3% | Buy | 19.3x | 30 |
Quick answers to the most common questions about buying SGMT stock.
The consensus Wall Street price target for SGMT is $20, representing 103.0% upside from the current price of $9.85. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SGMT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $20 implies 103.0% upside from current levels.
SGMT's current price is $9.85 with a consensus target of $20 (103.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $29 for SGMT, while the most conservative target is $7. The consensus of $20 represents the median expectation. These targets typically reflect 12-month expectations.
SGMT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SGMT stock forecast based on 9 Wall Street analysts shows a consensus price target of $20, with estimates ranging from $7 (bear case) to $29 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SGMT, with a "Buy" consensus rating and $20 price target (103.0% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SGMT analyst price targets range from $7 to $29, a 110% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.